January 22, 2007 -- Looking for an example of the convergence of medical devices and drug development? Oculus Innovative Sciences might be the poster child for this convergence. Oculus, which is scheduled to make its IPO this week, has won approval for Dermacyn as a device, with a CE Mark in Europe and 510(k) clearance in the US. As a device, it is approved for wound cleaning, or debridement, lubricating, moistening and dressing wounds. But the compound is also undergoing clinical trials so that it can be approved as a drug, in which case it would be indicated for wound healing. We look at Oculus, its product and its finances...
